Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1997 Sep;41(9):1880–1887. doi: 10.1128/aac.41.9.1880

Saquinavir-mediated inhibition of human immunodeficiency virus (HIV) infection in SCID mice implanted with human fetal thymus and liver tissue: an in vivo model for evaluating the effect of drug therapy on HIV infection in lymphoid tissues.

M Pettoello-Mantovani 1, T R Kollmann 1, C Raker 1, A Kim 1, S Yurasov 1, R Tudor 1, H Wiltshire 1, H Goldstein 1
PMCID: PMC164029  PMID: 9303378

Abstract

Treatment with protease inhibitors alone or in combination with inhibitors of reverse transcriptase potently suppresses levels of human immunodeficiency virus (HIV) RNA in plasma and thereby may significantly delay the progression of HIV-mediated disease. To investigate the effect of treatment with the protease inhibitor saquinavir on HIV replication in the lymphoid tissues, we used a SCID-hu mouse model that we developed, in which human thymic and liver tissues (hu-thy/liv) were implanted under both kidney capsules in SCID mice (thy/liv-SCID-hu mice). These mice are populated in the periphery with large numbers of human T cells and develop disseminated HIV infection after intraimplant injection. thy/liv-SCID-hu mice with established HIV infection that were treated for 1 month with saquinavir had a significantly lower viral load present in the implanted hu-thy/liv and mouse spleen than did the untreated HIV-infected thy/liv-SCID-hu mice. To examine the capacity of acute treatment with saquinavir to prevent HIV infection, some thy/liv-SCID-hu mice were inoculated with HIV and then immediately started on saquinavir. Although treated mice had markedly lower viral loads in the thy/liv implants and spleens, HIV infection was not completely prevented. Thus, the effect of antiviral therapy on HIV infection in the major site of HIV replication, the lymphoid tissues, can be readily evaluated in our thy/liv-SCID-hu mice. These mice should prove to be a useful model for determining the in vivo effectiveness of different therapeutic interventions on acute and chronic HIV infection.

Full Text

The Full Text of this article is available as a PDF (567.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Coffin J. M. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science. 1995 Jan 27;267(5197):483–489. doi: 10.1126/science.7824947. [DOI] [PubMed] [Google Scholar]
  2. Condra J. H., Schleif W. A., Blahy O. M., Gabryelski L. J., Graham D. J., Quintero J. C., Rhodes A., Robbins H. L., Roth E., Shivaprakash M. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature. 1995 Apr 6;374(6522):569–571. doi: 10.1038/374569a0. [DOI] [PubMed] [Google Scholar]
  3. Craig J. C., Duncan I. B., Hockley D., Grief C., Roberts N. A., Mills J. S. Antiviral properties of Ro 31-8959, an inhibitor of human immunodeficiency virus (HIV) proteinase. Antiviral Res. 1991 Dec;16(4):295–305. doi: 10.1016/0166-3542(91)90045-s. [DOI] [PubMed] [Google Scholar]
  4. Danner S. A., Carr A., Leonard J. M., Lehman L. M., Gudiol F., Gonzales J., Raventos A., Rubio R., Bouza E., Pintado V. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. European-Australian Collaborative Ritonavir Study Group. N Engl J Med. 1995 Dec 7;333(23):1528–1533. doi: 10.1056/NEJM199512073332303. [DOI] [PubMed] [Google Scholar]
  5. Eberle J., Bechowsky B., Rose D., Hauser U., von der Helm K., Gürtler L., Nitschko H. Resistance of HIV type 1 to proteinase inhibitor Ro 31-8959. AIDS Res Hum Retroviruses. 1995 Jun;11(6):671–676. doi: 10.1089/aid.1995.11.671. [DOI] [PubMed] [Google Scholar]
  6. Embretson J., Zupancic M., Ribas J. L., Burke A., Racz P., Tenner-Racz K., Haase A. T. Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS. Nature. 1993 Mar 25;362(6418):359–362. doi: 10.1038/362359a0. [DOI] [PubMed] [Google Scholar]
  7. Fauci A. S. Multifactorial nature of human immunodeficiency virus disease: implications for therapy. Science. 1993 Nov 12;262(5136):1011–1018. doi: 10.1126/science.8235617. [DOI] [PubMed] [Google Scholar]
  8. Ho D. D., Moudgil T., Alam M. Quantitation of human immunodeficiency virus type 1 in the blood of infected persons. N Engl J Med. 1989 Dec 14;321(24):1621–1625. doi: 10.1056/NEJM198912143212401. [DOI] [PubMed] [Google Scholar]
  9. Ho D. D., Neumann A. U., Perelson A. S., Chen W., Leonard J. M., Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature. 1995 Jan 12;373(6510):123–126. doi: 10.1038/373123a0. [DOI] [PubMed] [Google Scholar]
  10. Jacobsen H., Yasargil K., Winslow D. L., Craig J. C., Kröhn A., Duncan I. B., Mous J. Characterization of human immunodeficiency virus type 1 mutants with decreased sensitivity to proteinase inhibitor Ro 31-8959. Virology. 1995 Jan 10;206(1):527–534. doi: 10.1016/s0042-6822(95)80069-7. [DOI] [PubMed] [Google Scholar]
  11. Kitchen V. S., Skinner C., Ariyoshi K., Lane E. A., Duncan I. B., Burckhardt J., Burger H. U., Bragman K., Pinching A. J., Weber J. N. Safety and activity of saquinavir in HIV infection. Lancet. 1995 Apr 15;345(8955):952–955. doi: 10.1016/s0140-6736(95)90699-1. [DOI] [PubMed] [Google Scholar]
  12. Kollmann T. R., Kim A., Pettoello-Mantovani M., Hachamovitch M., Rubinstein A., Goldstein M. M., Goldstein H. Divergent effects of chronic HIV-1 infection on human thymocyte maturation in SCID-hu mice. J Immunol. 1995 Jan 15;154(2):907–921. [PubMed] [Google Scholar]
  13. Kollmann T. R., Pettoello-Mantovani M., Katopodis N. F., Hachamovitch M., Rubinstein A., Kim A., Goldstein H. Inhibition of acute in vivo human immunodeficiency virus infection by human interleukin 10 treatment of SCID mice implanted with human fetal thymus and liver. Proc Natl Acad Sci U S A. 1996 Apr 2;93(7):3126–3131. doi: 10.1073/pnas.93.7.3126. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Kollmann T. R., Pettoello-Mantovani M., Zhuang X., Kim A., Hachamovitch M., Smarnworawong P., Rubinstein A., Goldstein H. Disseminated human immunodeficiency virus 1 (HIV-1) infection in SCID-hu mice after peripheral inoculation with HIV-1. J Exp Med. 1994 Feb 1;179(2):513–522. doi: 10.1084/jem.179.2.513. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Kollmann T. R., Zhuang X., Rubinstein A., Goldstein H. Design of polymerase chain reaction primers for the selective amplification of HIV-1 RNA in the presence of HIV-1 DNA. AIDS. 1992 Jun;6(6):547–552. doi: 10.1097/00002030-199206000-00004. [DOI] [PubMed] [Google Scholar]
  16. Krone W. J., Sninsky J. J., Goudsmit J. Detection and characterization of HIV-1 by polymerase chain reaction. J Acquir Immune Defic Syndr. 1990;3(5):517–524. [PubMed] [Google Scholar]
  17. Markowitz M., Saag M., Powderly W. G., Hurley A. M., Hsu A., Valdes J. M., Henry D., Sattler F., La Marca A., Leonard J. M. A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N Engl J Med. 1995 Dec 7;333(23):1534–1539. doi: 10.1056/NEJM199512073332204. [DOI] [PubMed] [Google Scholar]
  18. McCune J. M. HIV-1: the infective process in vivo. Cell. 1991 Jan 25;64(2):351–363. doi: 10.1016/0092-8674(91)90644-e. [DOI] [PubMed] [Google Scholar]
  19. McCune J. M., Namikawa R., Shih C. C., Rabin L., Kaneshima H. Suppression of HIV infection in AZT-treated SCID-hu mice. Science. 1990 Feb 2;247(4942):564–566. doi: 10.1126/science.2300816. [DOI] [PubMed] [Google Scholar]
  20. McCune J. M., Péault B., Streeter P. R., Rabin L. Preclinical evaluation of human hematolymphoid function in the SCID-hu mouse. Immunol Rev. 1991 Dec;124:45–62. doi: 10.1111/j.1600-065x.1991.tb00615.x. [DOI] [PubMed] [Google Scholar]
  21. Namikawa R., Kaneshima H., Lieberman M., Weissman I. L., McCune J. M. Infection of the SCID-hu mouse by HIV-1. Science. 1988 Dec 23;242(4886):1684–1686. doi: 10.1126/science.3201256. [DOI] [PubMed] [Google Scholar]
  22. Pantaleo G., Graziosi C., Butini L., Pizzo P. A., Schnittman S. M., Kotler D. P., Fauci A. S. Lymphoid organs function as major reservoirs for human immunodeficiency virus. Proc Natl Acad Sci U S A. 1991 Nov 1;88(21):9838–9842. doi: 10.1073/pnas.88.21.9838. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Pantaleo G., Graziosi C., Demarest J. F., Butini L., Montroni M., Fox C. H., Orenstein J. M., Kotler D. P., Fauci A. S. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature. 1993 Mar 25;362(6418):355–358. doi: 10.1038/362355a0. [DOI] [PubMed] [Google Scholar]
  24. Pennisi E., Cohen J. Eradicating HIV from a patient: not just a dream? Science. 1996 Jun 28;272(5270):1884–1884. doi: 10.1126/science.272.5270.1884. [DOI] [PubMed] [Google Scholar]
  25. Perelson A. S., Neumann A. U., Markowitz M., Leonard J. M., Ho D. D. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science. 1996 Mar 15;271(5255):1582–1586. doi: 10.1126/science.271.5255.1582. [DOI] [PubMed] [Google Scholar]
  26. Piatak M., Jr, Saag M. S., Yang L. C., Clark S. J., Kappes J. C., Luk K. C., Hahn B. H., Shaw G. M., Lifson J. D. High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR. Science. 1993 Mar 19;259(5102):1749–1754. doi: 10.1126/science.8096089. [DOI] [PubMed] [Google Scholar]
  27. Richman D. D. HIV therapeutics. Science. 1996 Jun 28;272(5270):1886–1888. doi: 10.1126/science.272.5270.1886. [DOI] [PubMed] [Google Scholar]
  28. Ridky T., Leis J. Development of drug resistance to HIV-1 protease inhibitors. J Biol Chem. 1995 Dec 15;270(50):29621–29623. doi: 10.1074/jbc.270.50.29621. [DOI] [PubMed] [Google Scholar]
  29. Schapiro J. M., Winters M. A., Stewart F., Efron B., Norris J., Kozal M. J., Merigan T. C. The effect of high-dose saquinavir on viral load and CD4+ T-cell counts in HIV-infected patients. Ann Intern Med. 1996 Jun 15;124(12):1039–1050. doi: 10.7326/0003-4819-124-12-199606150-00003. [DOI] [PubMed] [Google Scholar]
  30. Schnittman S. M., Greenhouse J. J., Lane H. C., Pierce P. F., Fauci A. S. Frequent detection of HIV-1-specific mRNAs in infected individuals suggests ongoing active viral expression in all stages of disease. AIDS Res Hum Retroviruses. 1991 Apr;7(4):361–367. doi: 10.1089/aid.1991.7.361. [DOI] [PubMed] [Google Scholar]
  31. Wei X., Ghosh S. K., Taylor M. E., Johnson V. A., Emini E. A., Deutsch P., Lifson J. D., Bonhoeffer S., Nowak M. A., Hahn B. H. Viral dynamics in human immunodeficiency virus type 1 infection. Nature. 1995 Jan 12;373(6510):117–122. doi: 10.1038/373117a0. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES